MX2011011488A - Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina. - Google Patents

Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina.

Info

Publication number
MX2011011488A
MX2011011488A MX2011011488A MX2011011488A MX2011011488A MX 2011011488 A MX2011011488 A MX 2011011488A MX 2011011488 A MX2011011488 A MX 2011011488A MX 2011011488 A MX2011011488 A MX 2011011488A MX 2011011488 A MX2011011488 A MX 2011011488A
Authority
MX
Mexico
Prior art keywords
pyrrolo
triazole
pyridine derivates
compounds
derivates
Prior art date
Application number
MX2011011488A
Other languages
English (en)
Inventor
Dieter Dorsch
Thomas J J Mueller
Eugen Merkul
Margarita Wucherer-Plietker
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2011011488A publication Critical patent/MX2011011488A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la fórmula I (ver fórmula (I)) en donde R1, R2 y R3 tienen los significados indicados en la reivindicación 1, son inhibidores de la PDK1 y la proliferación celular / vitalidad celular y se pueden emplear para el tratamiento de tumores.
MX2011011488A 2009-05-05 2010-04-08 Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina. MX2011011488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009019962A DE102009019962A1 (de) 2009-05-05 2009-05-05 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
PCT/EP2010/002207 WO2010127754A1 (de) 2009-05-05 2010-04-08 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate

Publications (1)

Publication Number Publication Date
MX2011011488A true MX2011011488A (es) 2011-11-18

Family

ID=42315620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011488A MX2011011488A (es) 2009-05-05 2010-04-08 Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina.

Country Status (17)

Country Link
US (1) US8541584B2 (es)
EP (1) EP2427461B1 (es)
JP (1) JP5731481B2 (es)
KR (1) KR20120014183A (es)
CN (1) CN102414211B (es)
AR (1) AR076750A1 (es)
AU (1) AU2010244772B2 (es)
BR (1) BRPI1014459A2 (es)
CA (1) CA2760844C (es)
DE (1) DE102009019962A1 (es)
EA (1) EA201101585A1 (es)
ES (1) ES2436445T3 (es)
IL (1) IL215725A (es)
MX (1) MX2011011488A (es)
SG (1) SG175245A1 (es)
WO (1) WO2010127754A1 (es)
ZA (1) ZA201108885B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010049877A1 (de) * 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011008352A1 (de) 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
DE102011105469A1 (de) * 2011-06-24 2012-12-27 Merck Patent Gmbh 7-Azaindolderivate
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
BR112014032913A2 (pt) 2012-06-29 2017-06-27 Pfizer novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
BR112017005128A2 (pt) 2014-09-16 2018-07-31 Celgene Quanticel Res Inc inibidores de histona desmetilase
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AU2015320675B2 (en) 2014-09-26 2018-10-18 Gilead Sciences, Inc. Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
US10316049B2 (en) 2015-12-17 2019-06-11 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
CN115322192B (zh) * 2022-08-15 2023-07-14 重庆文理学院 吡咯并[3,4-b]吡啶类衍生物及其合成方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0405055D0 (en) * 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
JP2011500806A (ja) * 2007-10-25 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
DE102008038221A1 (de) * 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate

Also Published As

Publication number Publication date
CN102414211A (zh) 2012-04-11
DE102009019962A1 (de) 2010-11-11
CA2760844A1 (en) 2010-11-11
US20120053178A1 (en) 2012-03-01
EA201101585A1 (ru) 2012-05-30
JP5731481B2 (ja) 2015-06-10
AU2010244772A1 (en) 2011-12-22
KR20120014183A (ko) 2012-02-16
ES2436445T3 (es) 2014-01-02
JP2012526057A (ja) 2012-10-25
SG175245A1 (en) 2011-12-29
WO2010127754A1 (de) 2010-11-11
CN102414211B (zh) 2014-06-04
US8541584B2 (en) 2013-09-24
ZA201108885B (en) 2012-08-29
IL215725A0 (en) 2012-01-31
CA2760844C (en) 2017-09-19
EP2427461A1 (de) 2012-03-14
EP2427461B1 (de) 2013-10-09
BRPI1014459A2 (pt) 2016-04-05
AU2010244772B2 (en) 2016-01-07
IL215725A (en) 2014-12-31
AR076750A1 (es) 2011-07-06

Similar Documents

Publication Publication Date Title
MX2011011488A (es) Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina.
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
MX2013008212A (es) Derivados de 7-azaindol.
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
MY159230A (en) P38 map kinase inhibitors
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
NZ596571A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MX2013012979A (es) Piridina y derivados de pirazina.
NZ597517A (en) 5-fluoropyrimidinone derivatives
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
MY162933A (en) Chemical compounds
MX2009012708A (es) Derivados de piridazinona.
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2014013090A (es) Derivados de pirrolotriazinona.
MX2010003368A (es) Derivados de imidazol.
WO2011101069A3 (en) 1, 8 -naphthyridines as kinase inhibitors
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
MX345127B (es) Derivados de tiazol.
HK1139941A1 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal